Osimertinib CAS NO 1421373-65-0 Inquire about Osimertinib

Tecoland supplies Osimertinib bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Our Osimertinib is manufactured by cGMP compliant facility. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.

What is Osimertinib?

Osimertinib (previously known as mereletinib; trade name Tagrisso) is a medication used to treat non-small-cell lung carcinomas with a specific mutation. Developed by AstraZeneca, the medication was approved as a cancer treatment in 2017 by both the Food and Drug Administration and the European Commission.

Medical uses:

Osimertinib is used to treat locally advanced or metastatic non-small-cell lung cancer (NSCLC), if the cancer cells are positive for the T790M mutation in the gene coding for EGFR. The T790M mutation may be de novo or acquired following first-line treatment with other tyrosine kinase inhibitors, such as gefitinib and afatinib. It causes fetal harm, so should not be used in women who are pregnant, and women who take it should avoid becoming pregnant.

Mechanism of Action:

It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, which acts by blocking the activity of the epidermal growth factor receptor (EGFR). The EGFR in the lungs causes growth and uncontrolled division of cancer cells.

Pharmacology:

It binds irreversibly to EGFR with a L858R mutation and with an exon 19 deletion.It exhibits linear pharmacokinetics; the median time to Cmax is 6 hours (range 3–24 hours). The estimated mean half-life is 48 hours, and oral clearance (CL/F) is 14.2 (L/h). 68% of elimination is by feces and 14% by urine.

Disclaimer:

Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.